FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088734576> ?p ?o ?g. }

• W2088734576 abstract "You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy II1 Apr 20101498 TESTOSTERONE REPLACEMENT THERAPY IN HIGH RISK PATIENTS FOLLOWING RADICAL PROSTATECTOMY Kumaran Sathyamoorthy, Marshall Stein, Osama Mohammed, Larry Lipshultz, and Mohit Khera Kumaran SathyamoorthyKumaran Sathyamoorthy Houston, TX More articles by this author , Marshall SteinMarshall Stein New Orleans, LA More articles by this author , Osama MohammedOsama Mohammed Houston, TX More articles by this author , Larry LipshultzLarry Lipshultz Houston, TX More articles by this author , and Mohit KheraMohit Khera Houston, TX More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1235AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Testosterone replacement therapy (TRT) is the main treatment for symptomatic hypogonadism, and can help mitigate the sequelae of hypogonadism such as increased cardiovascular disease, erectile dysfunction and osteoporosis. However, significant controversy exists regarding the role of TRT in patients with a history of prostate cancer. Several series have demonstrated the low risk of PSA biochemical recurrence with TRT in radical prostatectomy (RP) patients. We present the largest series in the literature of post RP patients receiving TRT, and the first data on the risk of TRT in a series of high risk patients following RP. METHODS A total of 133 hypogonadal patients with history of RP were treated with TRT. Of these patients, 21 were classified as high risk (Gleason greater than or equal to 8, positive margins or node positive disease). Patients were all started on TRT for symptomatic hypogonadism following RP. Serum prostate specific antigen (PSA) and testosterone levels were measured every three months. Data analysis was completed with SPSS. RESULTS Mean patient age was 64.9 years. Patients were followed for a mean of 363 days. There were no PSA recurrences, and there was no statistically significant increase in PSA over the course of treatment. Among high risk patients, eight patients had a Gleason 8 or greater, 16 had positive margins and 1 patient had a positive lymph node. Mean PSA was .003 ng/mL (+/- .001) at the start of therapy, .016 (+/- .027) at three months, .011 (+/- .008) at six months, .010 (+/- .01) at 9 months, .010 (+/- .01) at 12 months and .01 (+/-.008) at 15 months. Testosterone increased from 262 to 418 ng/dL. There was no significant change in PSA during the duration of treatment (p > .05 at all intervals). CONCLUSIONS These data demonstrate that there was no statistically significant change in PSA among men placed on TRT with a history of RP and high risk characteristics. Although these results are encouraging, randomized clinical trials are needed to validate these findings. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e577 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kumaran Sathyamoorthy Houston, TX More articles by this author Marshall Stein New Orleans, LA More articles by this author Osama Mohammed Houston, TX More articles by this author Larry Lipshultz Houston, TX More articles by this author Mohit Khera Houston, TX More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2088734576 created "2016-06-24" @default.
• W2088734576 creator A5010030105 @default.
• W2088734576 creator A5025701604 @default.
• W2088734576 creator A5035179934 @default.
• W2088734576 creator A5085087432 @default.
• W2088734576 creator A5087500960 @default.
• W2088734576 date "2010-04-01" @default.
• W2088734576 modified "2023-09-26" @default.
• W2088734576 title "1498 TESTOSTERONE REPLACEMENT THERAPY IN HIGH RISK PATIENTS FOLLOWING RADICAL PROSTATECTOMY" @default.
• W2088734576 doi "https://doi.org/10.1016/j.juro.2010.02.1235" @default.
• W2088734576 hasPublicationYear "2010" @default.
• W2088734576 type Work @default.
• W2088734576 sameAs 2088734576 @default.
• W2088734576 citedByCount "6" @default.
• W2088734576 countsByYear W20887345762012 @default.
• W2088734576 countsByYear W20887345762013 @default.
• W2088734576 countsByYear W20887345762018 @default.
• W2088734576 countsByYear W20887345762020 @default.
• W2088734576 countsByYear W20887345762022 @default.
• W2088734576 countsByYear W20887345762023 @default.
• W2088734576 crossrefType "journal-article" @default.
• W2088734576 hasAuthorship W2088734576A5010030105 @default.
• W2088734576 hasAuthorship W2088734576A5025701604 @default.
• W2088734576 hasAuthorship W2088734576A5035179934 @default.
• W2088734576 hasAuthorship W2088734576A5085087432 @default.
• W2088734576 hasAuthorship W2088734576A5087500960 @default.
• W2088734576 hasConcept C121608353 @default.
• W2088734576 hasConcept C126322002 @default.
• W2088734576 hasConcept C126894567 @default.
• W2088734576 hasConcept C2777911890 @default.
• W2088734576 hasConcept C2779279991 @default.
• W2088734576 hasConcept C2779466945 @default.
• W2088734576 hasConcept C2779929075 @default.
• W2088734576 hasConcept C2780192828 @default.
• W2088734576 hasConcept C29456083 @default.
• W2088734576 hasConcept C3019419337 @default.
• W2088734576 hasConcept C3020768380 @default.
• W2088734576 hasConcept C71315377 @default.
• W2088734576 hasConcept C71924100 @default.
• W2088734576 hasConceptScore W2088734576C121608353 @default.
• W2088734576 hasConceptScore W2088734576C126322002 @default.
• W2088734576 hasConceptScore W2088734576C126894567 @default.
• W2088734576 hasConceptScore W2088734576C2777911890 @default.
• W2088734576 hasConceptScore W2088734576C2779279991 @default.
• W2088734576 hasConceptScore W2088734576C2779466945 @default.
• W2088734576 hasConceptScore W2088734576C2779929075 @default.
• W2088734576 hasConceptScore W2088734576C2780192828 @default.
• W2088734576 hasConceptScore W2088734576C29456083 @default.
• W2088734576 hasConceptScore W2088734576C3019419337 @default.
• W2088734576 hasConceptScore W2088734576C3020768380 @default.
• W2088734576 hasConceptScore W2088734576C71315377 @default.
• W2088734576 hasConceptScore W2088734576C71924100 @default.
• W2088734576 hasIssue "4S" @default.
• W2088734576 hasLocation W20887345761 @default.
• W2088734576 hasOpenAccess W2088734576 @default.
• W2088734576 hasPrimaryLocation W20887345761 @default.
• W2088734576 hasRelatedWork W1981635576 @default.
• W2088734576 hasRelatedWork W1992414199 @default.
• W2088734576 hasRelatedWork W2070332398 @default.
• W2088734576 hasRelatedWork W2314391848 @default.
• W2088734576 hasRelatedWork W2355655723 @default.
• W2088734576 hasRelatedWork W2508370915 @default.
• W2088734576 hasRelatedWork W2530461552 @default.
• W2088734576 hasRelatedWork W2612948534 @default.
• W2088734576 hasRelatedWork W2912438165 @default.
• W2088734576 hasRelatedWork W2982078558 @default.
• W2088734576 hasVolume "183" @default.
• W2088734576 isParatext "false" @default.
• W2088734576 isRetracted "false" @default.
• W2088734576 magId "2088734576" @default.
• W2088734576 workType "article" @default.